Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2010-11 trivalent inactivated influenza vaccine-British Columbia Centre for Disease Control-Influenza
- Development stage
- Unknown
- Lead developer
- British Columbia Centre for Disease Control
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 2010-11 trivalent inactivated influenza vaccine is a seasonal biologic used for the prevention of influenza infection. Formulated for the 2010-2011 Northern Hemisphere season, it contains inactivated viral components from three influenza strains: two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (specifically the B/Victoria lineage for this season). The vaccine functions by stimulating the immune system to produce neutralizing antibodies against the viral surface proteins hemagglutinin and neuraminidase. This specific vaccine was the subject of the TITRE IIB Follow-Up study conducted by the British Columbia Centre for Disease Control, which investigated the immune response in children to a second dose of the B/Victoria lineage following previous immunization with a B/Yamagata-containing vaccine in the 2008-09 season.
- Other names
- 2010-11 trivalent inactivated influenza vaccine2010-11 seasonal influenza vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on 2010-11 trivalent inactivated influenza vaccine-British Columbia Centre for Disease Control-Influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2010-11 trivalent inactivated influenza vaccine-British Columbia Centre for Disease Control-Influenza.